GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
By
Rowan Walrath
25d ago· 3 min readenNews
Summary
GSK has announced a $10.6 billion acquisition of Nuvalent, a biotech company developing small-molecule kinase inhibitors for treatment-resistant cancers. The deal, spearheaded by GSK's new CEO who is just 6 months into the role, marks a significant strategic move for the London-based pharmaceutical giant to bolster its oncology pipeline, particularly in lung cancer treatments.
Source
bskyGSK acquires cancer drug developer Nuvalent in $10.6 billion dealcen.acs.orgKey quotes
· 2 pulledJust 6 months into the job, GSK's CEO is spearheading some big moves.
The London-based pharma giant announced Tuesday that it will spend $10.6 billion to acquire Nuvalent, a developer of small-molecule kinase inhibitors for treatment-resistant cancer.
Biotech firm is developing small molecules for lung cancers
You might also wanna read
Novartis to buy UK biotech in $1.5bn deal
ft.com·8h ago
AdBiotech Becomes No. 2 Shareholder of Pet Healthcare Firm Onhil
Seoul Economic Daily·8h ago
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
STAT·4h ago
STAT+: Roche drug sets new standard for KRAS-driven lung cancer
STAT·4d ago
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
economist.com·23d ago
Cancer Research UK bets on Manchester with £6-million funding boost
Nature Communications
Comments
Sign in to join the conversation.
No comments yet. Be the first.